Vorbipiprant · CR6086

What is Vorbipiprant?

Vorbipiprant is an orally bioavailable small molecule antagonist of the prostaglandin E2 receptor EP4 (PTGER4). It blocks PGE2-EP4 signaling to inhibit tumor cell proliferation and prevent tumor-associated myeloid cell activity by reducing IL-23 production and Th17 cell expansion. It is studied in colorectal and gastric cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

CR6086

Drug type

Small molecule

Targets

prostaglandin E2 receptor subtype 4 (PTGER4)

Mechanism

Antagonist of prostaglandin E2 receptor subtype 4 (PTGER4)

Pathways

PGE2-EP4 signaling, IL-23 production, Th17 cell expansion

Therapy area

Oncology

Developer

Rottapharm Biotech

In trials of

AGEN

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1/2

UNII

TNK4EB6VB5

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Gastric CancerMetastatic GI CancersMetastatic Microsatellite-stable Colorectal CancerMismatch Repair Protein ProficientRefractory Metastatic Colorectal CancerSolid Tumor

Other drugs acting on PTGER4

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT05205330

Updated Oct 3, 2026.